In: プレスリリース

ジョナサン・サントマウロ氏は、フィラデルフィア・ビジネスジャーナルが毎年選出する「ダイナミックな新人」のリストにおいて、その会社とコミュニティに対する貢献を認められました。

ペンシルバニア州ホーシャム、2018年4月17日国際臨床および付属資材サプライチェーンの一流企業であり、バイオテクノロジーおよび医療機器企業、ならびに外部委託企業および医療研究機関のエンド・ツー・エンドの臨床および付属資材サプライチェーン・マネジメントを担当する唯一の組織であるAncillare、LPのジョナサン・サントマウロ社長兼共同創業者は、フィラデルフィア・ビジネスジャーナルによって、2018年の「40 Under 40」の受賞者に選出されました。

「40 Under 40」は、フィラデルフィア地域の現在および将来のリーダーを、プロフェッショナルとしての卓越性、優れた成功、地域社会への貢献度で評価しています。サントマウロ氏は、400以上もの候補者から選出されました。

サントマウロ氏は、臨床および付属資材サプライチェーン業界を統合することに尽力してきました。それは特に、業界の臨床サプライチェーンへのアプローチに革命をもたらすAncillareターンキー・オペレーション(A-TKO™)エンド・ツー・エンド・ソリューションの原動力として認識されています。これやその他のビジネスモデルを通じ、Ancillareは引き続き世界の臨床サプライチェーン業界の最前線に留まり、臨床試験の運用、タイムライン、現場のパフォーマンス、そして最終的には患者へのサービスに直接的な影響を与えます。

Ancillareは、起業組織から世界に200人以上の従業員を抱える国際組織に成長しました。今日では、世界のトップ製薬企業10社のうち8社、世界的なバイオテクノロジー企業5社のうち3社、および臨床研究機関のトップ2社は、第Ⅰ-Ⅳ相臨床試験および付属資材の供給要求を管理するためにAncillareに頼っています。

「フィラデルフィア・ビジネスジャーナルの『40 Under 40』の1つに選ばれることは非常に名誉なことです」とサンタマウロ氏は語りました。「臨床試験運営や世界中の患者のための、革新的な治療法開発に直接影響を与えるようなキャリアを送ることができたのは、とても幸せなことでした」

サンタマウロ氏は、YPO(かつてのYoung Presidents Organization)フィラデルフィア支部のメンバーとして地元のビジネス界で活躍し、コーネル大学の起業家精神評議会を長年務め、経営管理学修士と芸術学士を取得しています。

サンタマウロ氏は5月10日の木曜日、フィラデルフィアのSugarHouse Casinoで賞を受ける予定です。

Ancillare, LPについて

Ancillareは、世界規模の臨床および付属資材サプライチェーンを専門に扱う業界唯一の組織です。Ancillareは、カスタマイズされたエンド・ツー・エンドのAncillare供給プランを用いた国際的な臨床試験のスポンサーであり、広範な国際購買力、膨大な供給ネットワーク、臨床、調達、運営、物流、規制などの実績ある専門チームを用いて、新しい治療法の開発者が臨床研究のサプライチェーンを最適化することができます。Ancillareのターンキー・オペレーション(A-TKO ™)モデルは、臨床試験の全体的なコストとサイクルタイムの両方を削減することで、臨床的および付属資材サプライチェーンの複雑さと国際化を取り入れ、バリューチェーンのあらゆるレベルでの業務効率を大幅に改善します。

Ancillareは、米国、英国、シンガポールに主要拠点を、さらに、アルゼンチン、オーストラリア、ブラジル、カナダ、チリ、中国、コロンビア、インド、イスラエル、日本、韓国、メキシコ、パナマ、ペルー、フィリピン、ロシア、南アフリカ、台湾、ウクライナに戦略的供給拠点を構え、100カ国以上、8万の臨床現場で1,500以上の臨床試験を支援しています。詳細は、Ancillare.comをご覧ください。

 

Approaching Brexit deadline, new licensure will enable continuous global clinical trial operations for sponsors and CROs

HORSHAM, PA. — January 31, 2018. Global Clinical and Ancillary Supply Chain leader Ancillare, LP, the only organization exclusively serving the end-to-end clinical and ancillary supply chain management needs of large- and middle-market pharmaceutical, biotechnology, and medical device companies, as well as contract and medical research organizations, today announced it has been awarded a Wholesale Distribution Authorization (WDA) for Human use by the United Kingdom Medicines and Healthcare Products Regulatory Agency (MHRA).

The award, which comes in response to the United Kingdom’s anticipated departure from the E.U.—commonly called “Brexit”—will allow Ancillare to continue to support study sponsors’ European needs, even while Brexit’s impact on pharmaceutical supply chains remains unclear. The licensure is a critical victory for the dozens of study sponsors, CROs and MROs for whom the U.K. market is a vital link in complex, global clinical trial portfolios and supply chains.

“I think [the license is] a testament to the integrity and dedication of our global team,” said Joanne Santomauro, CEO, Ancillare. “No matter how rapidly or exponentially things have changed on the global stage, we’ll always be ready to respond in service to our sponsors.”

Ancillare received the license following an intensive evaluation, auditing and inspections process. Among the qualifying criteria for the license was that Ancillare was in full compliance with the 2012 Human Medicines Regulations, and with the requirements of Good Distribution Practice (GDP). Ancillare’s WDA will enable ongoing wholesaling and distribution activities—including procurement, holding, supply and export—from its European regional office and master depot in Milton Keynes.

“I’m proud that Ancillare has emerged even better equipped to meet the clinical and ancillary supply chain needs of study sponsors,” Santomauro added.

In response to its confirmed regulatory compliance status, as well as ongoing Brexit requirements, Ancillare anticipates adding staff at its United Kingdom office, in order to drive global expansion efforts throughout Europe, the Middle East, Africa and Asia-Pacific. Ancillare expects to announce the staff changes later in Q1 2018.

 

About Ancillare, LP

Ancillare is the only organization of its kind with an exclusive focus on the global clinical and ancillary supply chain. Ancillare arms sponsors of global clinical trials with a customized, end-to-end Ancillare Supply Plan, enabling developers of new therapies to optimize their clinical study supply chains using streamlined processes, extensive global buying power, a vast depot network and proven teams of clinical, procurement, operations, logistics and regulatory experts. Ancillare’s Turn-Key Operations (A-TKO™) model embraces the complexities and globalization of the clinical and ancillary supply chain by reducing both the overall cost and cycle time of clinical trials, and greatly improving operational efficiency across all levels of the value chain.

Ancillare has supported more than 1,500 clinical trials across 80,000 clinical sites over 100 countries with master depots in United States, United Kingdom, and Singapore, and strategic depots in Argentina, Australia, Brazil, Canada, Chile, China, Colombia, India, Israel, Japan, Korea, Mexico, Panama, Peru, Philippines, Russia, South Africa, Taiwan, and Ukraine. To learn more, visit ancillare.com.

HORSHAM, PA. — Global Clinical and Ancillary Supply Chain leader Ancillare, LP—the only organization exclusively serving the end-to-end clinical and ancillary supply chain management needs of large- and middle-market pharmaceutical, biotechnology, and medical device companies, as well as contract and medical research organizations—today announced that David J. DelCollo, Esq., its primary in-house counsel, has been awarded both “Top 100 Lawyer” and “Top 40 Under 40” recognitions.

The recognitions come on the heels of DelCollo’s first year as Ancillare’s general counsel. Prior to joining Ancillare, he served as Senior Counsel for Bioclinica, where he worked to develop and protect the company’s intellectual property and licensing rights. DelCollo brought more than a decade of legal experience in practice areas such as corporate, contract and healthcare law to Ancillare—knowledge which he made quick use of, according to Ancillare leadership.

“David has made tremendous contributions this year and I think these awards are apropos,” said Joanne Santomauro, CEO at Ancillare. “He’s a skilled attorney. Not only as he helped [Ancillare] define our legal policies, he’s put us on a path to a more secure future.”

Prior to his success in corporate law, DelCollo represented the Commonwealth in the courtroom. As an Assistant District Attorney in the Greater Philadelphia Area, he personally prosecuted over 1,000 cases, winning favorable verdicts and outcomes 97% of the time.

DelCollo holds a J.D. from Widener University School of Law, where he was a member of the Trial Advocacy team.

The recognition of “Top 100 Lawyer” was awarded by executive profile publication International Top 100 Magazine. DelCollo’s “Top 40 Under 40” spotlight will be featured a forthcoming 2018 edition of the same magazine.

About Ancillare, LP

Ancillare is the only organization of its kind with a singular focus on the global clinical and ancillary supply chain. Ancillare arms sponsors of global clinical trials with a customized, end-to-end Ancillare Supply Plan, enabling developers of new therapies to optimize their clinical study supply chains using streamlined processes, extensive global buying power, a vast depot network and proven teams of clinical, procurement, operations, logistics and regulatory experts. Ancillare’s A-TKO™ model embraces the complexities and globalization of the clinical and ancillary supply chain by reducing both the overall cost and cycle time of clinical trials, and greatly improves operational efficiency across all levels of the value chain.

Ancillare has experience in working over 100 countries with master depots in United States, United Kingdom, and Singapore, and strategic depots in Argentina, Australia, Brazil, Canada, Chile, China, Colombia, India, Israel, Japan, Korea, Mexico, Panama, Peru, Philippines, Russia, South Africa, Taiwan, and Ukraine.